Ketamine for Suicidal Ideation

💜 Ketamine Therapy for Suicidal Ideation: What You Need to Know

Suicidal thoughts or behavior require immediate assessment by qualified crisis or emergency professionals. This directory is not a crisis service and should not be used to choose outpatient treatment during an emergency.

Research has examined ketamine and esketamine in carefully monitored clinical settings. In 2020, FDA approved Spravato for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior, together with an oral antidepressant and comprehensive standard care. FDA prescribing information expressly states that Spravato has not been shown to prevent suicide or reduce suicidal ideation or behavior, and it does not replace hospitalization when clinically warranted.

How Ketamine Works for Suicidal Ideation

Researchers continue to study whether changes in glutamate signaling and other pathways may contribute to rapid changes in depressive symptoms. These proposed mechanisms do not establish that ketamine prevents suicide, and findings from controlled research should not be generalized into an emergency-treatment recommendation. Evaluation, safety planning, hospitalization when warranted, and continuing psychiatric care remain essential.

Clinical Evidence

Small trials and meta-analyses have reported short-term changes in measured suicidal ideation after IV ketamine. The Spravato ASPIRE trials supported an indication for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, but did not demonstrate prevention of suicide or a reduction in suicidal ideation or behavior. The current FDA prescribing information should control over summaries of individual studies.

Who Is a Candidate?

Only a qualified clinician can determine whether ketamine or Spravato is appropriate after a full assessment. A person with active suicidal thoughts should contact 988, emergency services, or an emergency department rather than rely on this directory or wait for an outpatient clinic appointment. Spravato must be administered in a certified healthcare setting under direct supervision and does not eliminate the need for hospitalization.

Side Effects to Consider

Side effects of ketamine when used for suicidal ideation are consistent with those in depression treatment: dissociation, sedation, dizziness, nausea, and elevated blood pressure. Given the clinical acuity of suicidal patients, safety monitoring is particularly rigorous. Patients receiving Spravato must remain in the clinic for at least two hours after administration and are assessed for sedation and dissociation before discharge. Patients must not drive on the day of treatment and should have a responsible companion available. All patients receiving ketamine for suicidal ideation should be engaged in comprehensive psychiatric care including therapy and medication management.

Frequently Asked Questions

Common questions about ketamine therapy for acute suicidal ideation.

References

1. Price RB et al. (2014) Depress Anxiety. RCT demonstrated ketamine significantly reduced explicit suicidal cognition within 24 hours compared to midazolam in treatment-resistant depression. [DOI]
2. Wilkinson ST et al. (2018) Am J Psychiatry. Individual participant data meta-analysis found a single dose of IV ketamine rapidly reduced suicidal ideation within one day, with effects lasting up to one week. [DOI]
3. Grunebaum MF et al. (2018) Am J Psychiatry. Ketamine significantly reduced suicidal ideation within 24 hours compared to midazolam in a randomized clinical trial. [DOI]
4. Fu DJ et al. (2020) J Clin Psychiatry. ASPIRE-I trial showed esketamine nasal spray plus standard of care rapidly reduced depressive symptoms including suicidal ideation in patients at imminent risk. [DOI]